Skip to content
Screener

Interest Expense at other companies

Immunovant, Inc. logo
Immunovant, Inc.IMVT
$8.06M+17.0%
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
$1.22M+288%
Celcuity logo
CelcuityCELC
$6.09M+91.2%

Other financials

Income statement

See full
Revenue$9.0M-61.3%
Operating income-$49.1M-216%
Net income-$43.4M-253%
EPS (diluted)-$0.43-187%

Balance sheet

See full
Cash & equivalents$90.1M+29.8%
Total debt$38.0M-7.6%
Total equity$487.3M+81.8%
Total assets$691.2M+92.2%

Cash flow

See full
Operating cash flow-$44.1M-27.1%
CapEx$4.7M+179%
Free cash flow-$48.8M-34.1%

Valuation

See full
Market cap$1.35B+424%
Enterprise value$1.3B+465%
P/S47.2×+45.7×

Profitability

See full
Operating margin-633%
Net margin-560.8%
FCF margin-111.7%-125pp

Returns & leverage

See full
Return on equity-42.7%
Debt / equity0.1×-0.1×
Current ratio10.6×+3.4×

Where this comes from

Reported directly by Monte Rosa Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:InterestIncomeExpenseNonoperatingNet.

The source filing: Monte Rosa Therapeutics, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 7:09 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-336711
(in thousands, except share and per share amounts)Three months ended June 30, 2026Three months ended June 30, 2025Six months ended June 30, 2026Six months ended June 30, 2025
Total operating expenses58,09838,748112,34279,641
(Loss) income from operations(49,130)(15,554)(99,164)28,482
Other income:
Interest income5,9163,06811,5076,507
Foreign currency exchange gain251,390171,563
Gain on disposal of property and equipment59
Total other income5,9414,45811,5248,129
Net (loss) income before income taxes(43,189)(11,096)(87,640)36,611

Item 1. Financial Statements

FAQ

What is Monte Rosa Therapeutics, Inc.'s interest expense?
Monte Rosa Therapeutics, Inc. (GLUE) reported interest expense of $5.92M in Q2 2026.
How has Monte Rosa Therapeutics, Inc.'s interest expense changed year-over-year?
Monte Rosa Therapeutics, Inc.'s interest expense increased by 92.8% year-over-year, from $3.07M to $5.92M.
What is the long-term trend for Monte Rosa Therapeutics, Inc.'s interest expense?
Over 4 years (2021 to 2025), Monte Rosa Therapeutics, Inc.'s interest expense has grown at a 309.6% compound annual growth rate (CAGR), from $46K to $12.94M.
What does interest expense mean?
Cost of borrowing — interest paid or accrued on bonds, bank loans, credit facilities, finance leases, and other debt obligations.

Ask your AI about Monte Rosa Therapeutics, Inc.'s interest expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude